{"article_title": "Why Abbott Laboratories' Healthy Dividend Belongs on Your Radar", "article_keywords": ["abbott", "buy", "healthy", "thematically", "oversold", "charts", "stocks", "radar", "say", "belongs", "attractive", "nooppenheimer", "dividend", "laboratories", "beginning", "technical"], "article_url": "http://www.thestreet.com/story/13416365/1/why-abbott-laboratories-healthy-dividend-belongs-on-your-radar.html", "article_text": "Should You Buy These 6 Oversold Stocks? The Charts Say No\n\nOppenheimer says these six stocks -- down 10% or more since the beginning of April -- are 'thematically attractive,' but the technical charts say otherwise.", "article_metadata": {"layout": "main", "description": "Given Abbott's track record of raising its dividend, it's become a must-own stock for the next five years.", "author": "Richard Saintvilus", "og": {"site_name": "TheStreet", "description": "Given Abbott's track record of raising its dividend, it's become a must-own stock for the next five years.", "title": "Why Abbott Labs' Healthy Dividend Belongs on Your Radar", "url": "https://www.thestreet.com/story/13416365/1/why-abbott-laboratories-healthy-dividend-belongs-on-your-radar.html", "image": {"width": 600, "secure_url": "https://s.thestreet.com/files/tsc/v2008/photos/contrib/uploads/abbottlabssign.jpg", "identifier": "http://s.thestreet.com/files/tsc/v2008/photos/contrib/uploads/abbottlabssign.jpg", "height": 400}, "locale": "en_US", "type": "article"}, "section": "Investing -- Opinion", "robots": "NOYDIR", "keywords": "Abbot Laboratories, Stock Investing, Dividends, Affordable Care Act, Opinion", "fb": {"app_id": 458919507482096}, "article": {"publisher": "https://www.facebook.com/TheStreet", "published_time": "2016-01-08T06:15Z", "author": "https://www.thestreet.com/author/1258652/RichardSaintvilus/all.html", "section": "Investing -- Opinion", "modified_time": "2016-01-08T06:15Z", "tag": "Opinion"}, "date": "2016-01-08T06:15Z", "contentType": "article", "tst": {"article": "desktop"}, "guid": 13416365, "twitter": {"description": "Given Abbott's track record of raising its dividend, it's become a must-own stock for the next five years.", "title": "Why Abbott Labs' Healthy Dividend Belongs on Your Radar", "url": "https://www.thestreet.com/story/13416365/1/why-abbott-laboratories-healthy-dividend-belongs-on-your-radar.html", "image": {"src": "https://s.thestreet.com/files/tsc/v2008/photos/contrib/uploads/abbottlabssign.jpg", "identifier": "https://s.thestreet.com/files/tsc/v2008/photos/contrib/uploads/abbottlabssign.jpg"}, "site": "@TheStreet", "card": "summary_large_image"}, "viewport": "width=device-width, user-scalable=no", "news_keywords": "Abbot Laboratories, Stock Investing, Dividends, Affordable Care Act, Opinion"}, "article_summary": "The Charts Say NoOppenheimer says these six stocks -- down 10% or more since the beginning of April -- are 'thematically attractive,' but the technical charts say otherwise.\nShould You Buy These 6 Oversold Stocks?"}